AI Article Synopsis
- Glioblastoma is a highly aggressive brain tumor with a poor prognosis, and traditional chemotherapy methods have shown limited effectiveness in treating it.
- Recent innovations in nanotechnology and combination therapies may enhance treatment outcomes by increasing drug efficiency and reducing side effects compared to using single high-dose drugs.
- This review focuses on the advancements in using nanotechnology to co-deliver multiple therapeutic agents for glioblastoma, highlighting its potential for improving chemotherapy results.
Article Abstract
Glioblastoma is a malignant brain tumor and leads to death in most patients. Chemotherapy is a common method for brain cancer in clinics. However, the recent advancements in the chemotherapy of brain tumors have not been efficient enough. With the advancement of nanotechnology, the used drugs can enhance chemotherapy efficiency and increase the access to brain cancers. Combination of therapeutic agents has been recently attracted great attention for glioblastoma chemotherapy. One of the early benefits of combination therapies is the high potential to provide synergistic effects and decrease adverse side effects associated with high doses of single anticancer drugs. Therefore, brain tumor treatments with combination drugs can be considered as a crucial approach for avoiding tumor growth. This review investigates current progress in nano-mediated co-delivery of therapeutic agents with focus on glioblastoma chemotherapy prognosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msec.2016.07.080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!